Oncology News

The FDA approved pembrolizumab for use with chemotherapy to treat HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Over 10% of fecal immunochemical tests used for routine colorectal cancer screening contained unsatisfactory samples that could not be processed, according to study findings published in Cancer Epidemiology, Biomarkers and Prevention.

BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.

Risk for developing colorectal cancer increased by 47% among individuals with type 2 diabetes, according to results from a cohort study designed to over-represent African Americans and low-income patients.

BOSTON — Direct-acting antiviral therapy for hepatitis C virus-related hepatocellular carcinoma significantly improves overall survival, but only one in four patients receive therapy, even with insurance, according to a researcher.

Durvalumab combined with transarterial chemoembolization and bevacizumab lengthened PFS among certain patients with hepatocellular carcinoma, according to the agent’s manufacturer.

BOSTON — An educational program for transplant nurse coordinators did not improve advanced care planning among patients with decompensated cirrhosis, suggesting that provider training alone is “insufficient” to create significant change.

An automatic surveillance system that accurately identified patients after colorectal polypectomy and assigned surveillance intervals by risk improved guideline adherence among physicians and reduced staff workload, according to data.

The FDA revised an existing indication of pembrolizumab for the first-line treatment of certain patients with gastric or gastroesophageal junction adenocarcinoma.

The FDA approved fruquintinib for certain adults with previously treated metastatic colorectal cancer.